The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia.
antipsychotic
long-acting injections
quality of life
recovery
schizophrenia
subjective well-being
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
12
2018
accepted:
18
03
2019
entrez:
24
5
2019
pubmed:
24
5
2019
medline:
24
5
2019
Statut:
epublish
Résumé
Schizophrenia is a chronic syndrome involving different clinical dimensions, and causes significant disability with a negative impact on the quality of life of patients and their caregivers. Current guidelines for the treatment of schizophrenia focus on maximizing a patient's adaptive functioning and quality of life in a recovery-oriented approach that encourages active collaboration among patients, caregivers, and mental health professionals to design and manage a customized and comprehensive care plan. In the present study, a panel of experts (psychiatrists, psychologists, nurse, and social worker) gathered to review and explore the need for contemporary use of second-generation antipsychotic long-acting injectables (SGA LAIs) in "recovery-oriented" and "patient-centered" care of schizophrenia. Starting from the available data and from sharing personal attitudes and experiences, the panel selected three clinical dimensions considered useful in characterizing each patient: phase of disease, adherence to treatment, and level of functioning. For each clinical dimension, perspectives of patients and caregivers with regard to needs, expectations, and personal experiences were reviewed and the role of SGA LAIs in achieving shared goals examined. The experts concluded that from today's modern perspectives, SGA-LAIs may play an important role in breaking the spiral of desocialization and functional decline in schizophrenia, thus favoring the recovery process.
Identifiants
pubmed: 31118640
doi: 10.2147/NDT.S199048
pii: 199048
pmc: PMC6503342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1045-1060Déclaration de conflit d'intérêts
FP is/has been a consultant and/or a speaker for Janssen-Cilag, Lundbeck, Otsuka Pharmaceuticals, and Eli Lilly. UA is/has been a consultant and/or a speaker for Angelini, FB Health, Janssen Cilag, and Lundbeck. GM is/has been a consultant and/or a speaker and/or has received research grants from Angelini, Boheringer Ingelheim, FB Health, Italfarmaco, Janssen, Lundbeck, and Otsuka Pharmaceuticals. BC has participated as a consultant in scientific boards and as a speaker in industry-sponsored courses or symposia supported by Janssen Italy, Lundbeck Italy, Otsuka Italy, and ACRAF Angelini. The other authors report no conflicts of interest in this work.
Références
Am J Manag Care. 1997 Apr;3(4):579-94
pubmed: 10169526
Am J Psychiatry. 2000 Jun;157(6):1019-20
pubmed: 10831489
Schizophr Res. 2002 Jan 15;53(3):239-48
pubmed: 11738537
Psychol Med. 2000 Sep;30(5):1155-67
pubmed: 12027051
Schizophr Res. 2002 Oct 1;57(2-3):209-19
pubmed: 12223252
Am J Psychiatry. 2003 Feb;160(2):303-9
pubmed: 12562577
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
Gut. 2004 May;53 Suppl 4:iv40-4
pubmed: 15082613
Can J Psychiatry. 2004 May;49(5):290-6
pubmed: 15198464
Psychiatr Serv. 2004 Sep;55(9):997-1005
pubmed: 15345759
Acta Psychiatr Scand. 2005 Feb;111(2):81-3
pubmed: 15667426
Psychiatr Serv. 2006 Feb;57(2):205-11
pubmed: 16452697
Can J Psychiatry. 2005 Dec;50(14):892-900
pubmed: 16494258
Isr J Psychiatry Relat Sci. 2005;42(4):223-30
pubmed: 16618053
Postgrad Med. 2006 Sep;Spec No:5-19
pubmed: 17128657
J Clin Psychiatry. 2006 Nov;67(11):1690-7
pubmed: 17196047
J Clin Psychiatry. 2007 Jan;68(1):75-80
pubmed: 17284133
Acta Psychiatr Scand. 2007 Apr;115(4):260-7
pubmed: 17355516
Am J Psychiatry. 2007 Apr;164(4):630-7
pubmed: 17403977
Clin Pract Epidemiol Ment Health. 2007 Oct 29;3:23
pubmed: 17967165
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):755-60
pubmed: 18226436
Acta Psychiatr Scand. 2008 Sep;118(3):220-9
pubmed: 18699954
Schizophr Res. 2009 Feb;107(2-3):165-72
pubmed: 18842393
Epidemiol Psichiatr Soc. 2008 Jul-Sep;17(3):174-6
pubmed: 18924553
Int J Neuropsychopharmacol. 2009 Jun;12(5):715-21
pubmed: 19366489
Schizophr Bull. 2010 Jan;36(1):94-103
pubmed: 19955388
Hum Psychopharmacol. 2010 Apr;25(3):243-52
pubmed: 20373476
CNS Spectr. 2010 May;15(5):327-37
pubmed: 20448523
Soc Sci Med. 2010 Dec;71(12):2150-61
pubmed: 21051128
J Clin Psychiatry. 2011 Oct;72(10):1397-404
pubmed: 21208588
Aust N Z J Psychiatry. 2011 Mar;45(3):182-92
pubmed: 21438745
BMC Psychiatry. 2011 Sep 30;11:157
pubmed: 21961829
Trends Cogn Sci. 2012 Jan;16(1):9-10
pubmed: 22153582
Int J Soc Psychiatry. 2013 May;59(3):207-16
pubmed: 22222848
Clin Drug Investig. 2012 Apr 1;32(4):267-79
pubmed: 22339430
Health Qual Life Outcomes. 2012 Apr 02;10:35
pubmed: 22472127
Schizophr Res. 2012 Aug;139(1-3):211-7
pubmed: 22704996
Int Clin Psychopharmacol. 2012 Nov;27(6):336-49
pubmed: 22859065
Psychiatr Danub. 2012 Sep;24 Suppl 1:S95-9
pubmed: 22945197
Clin Pract Epidemiol Ment Health. 2012;8:52-66
pubmed: 22962559
Schizophr Res Treatment. 2012;2012:368687
pubmed: 22966435
Schizophr Res Treatment. 2012;2012:764769
pubmed: 22966444
Innov Clin Neurosci. 2012 Jul;9(7-8):17-23
pubmed: 22984648
BMC Psychiatry. 2012 Sep 19;12:150
pubmed: 22992395
World Psychiatry. 2012 Oct;11(3):161-2
pubmed: 23024668
Aust N Z J Psychiatry. 2013 Jul;47(7):624-30
pubmed: 23209308
World J Biol Psychiatry. 2013 Feb;14(1):2-44
pubmed: 23216388
Eur Psychiatry. 2002 Aug;17 Suppl 4:371s-375s
pubmed: 23573607
Clin Psychopharmacol Neurosci. 2013 Apr;11(1):1-6
pubmed: 23678347
CNS Drugs. 2013 Aug;27(8):625-36
pubmed: 23757184
Hum Psychopharmacol. 2013 Sep;28(5):457-65
pubmed: 23784674
Can J Psychiatry. 2013 May;58(5 Suppl 1):30S-5S
pubmed: 23945065
Psychiatry Res. 2013 Dec 30;210(3):739-44
pubmed: 24007858
World Psychiatry. 2013 Oct;12(3):216-26
pubmed: 24096780
BMC Psychiatry. 2013 Oct 16;13:261
pubmed: 24131801
Patient Prefer Adherence. 2013 Nov 13;7:1171-80
pubmed: 24265549
BMC Psychiatry. 2013 Sep 26;13:235
pubmed: 24294839
BMC Psychiatry. 2013 Dec 20;13:340
pubmed: 24359031
CNS Spectr. 2014 Feb;19(1):3-5
pubmed: 24512639
Psychiatr Q. 2015 Jun;86(2):199-205
pubmed: 25164199
World Psychiatry. 2014 Oct;13(3):275-87
pubmed: 25273301
Neuropsychiatr Dis Treat. 2014 Sep 24;10:1867-78
pubmed: 25285010
Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219
pubmed: 25360245
Psychiatr Danub. 2014 Dec;26(4):304-7
pubmed: 25377363
Int J Psychiatry Clin Pract. 2015 Jun;19(2):106-13
pubmed: 25410156
Clin Ther. 2014 Oct 1;36(10):1372-88.e1
pubmed: 25444566
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:1-7
pubmed: 25448776
Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13
pubmed: 25455704
Schizophr Res. 2015 Mar;162(1-3):276-84
pubmed: 25649288
Psychiatr Q. 2015 Dec;86(4):521-32
pubmed: 25663602
Int J Ment Health Nurs. 2015 Aug;24(4):295-303
pubmed: 25976922
J Psychopharmacol. 2015 Aug;29(8):910-22
pubmed: 25999398
JAMA Psychiatry. 2015 Aug;72(8):822-9
pubmed: 26107752
Patient Prefer Adherence. 2015 Jun 16;9:777-84
pubmed: 26124643
Int Clin Psychopharmacol. 2015 Nov;30(6):320-8
pubmed: 26196188
Early Interv Psychiatry. 2017 Dec;11(6):509-516
pubmed: 26256465
Early Interv Psychiatry. 2016 Oct;10(5):365-77
pubmed: 26403538
Psychiatr Serv. 2016 Feb;67(2):227-33
pubmed: 26467909
Am J Psychiatry. 2016 Apr 1;173(4):362-72
pubmed: 26481174
Neuropsychiatr Dis Treat. 2016 Jan 06;12:57-67
pubmed: 26792993
World Psychiatry. 2016 Feb;15(1):13-20
pubmed: 26833597
Ther Clin Risk Manag. 2016 Jan 27;12:109-16
pubmed: 26869795
Neuropsychiatr Dis Treat. 2016 Apr 19;12:917-29
pubmed: 27143893
Riv Psichiatr. 2016 Mar-Apr;51(2):47-59
pubmed: 27183509
Eur Arch Psychiatry Clin Neurosci. 2017 Jun;267(4):335-339
pubmed: 27194554
Drug Des Devel Ther. 2016 May 24;10:1731-42
pubmed: 27307704
Eur Arch Psychiatry Clin Neurosci. 2017 Jun;267(4):285-294
pubmed: 27381016
Eur Psychiatry. 2016 Sep;37:35-42
pubmed: 27442981
J Clin Psychopharmacol. 2016 Oct;36(5):492-5
pubmed: 27580495
J Clin Psychiatry. 2016;77(suppl 3):1-24
pubmed: 27732772
Br J Psychiatry. 2016 Nov;209(5):361-365
pubmed: 27802977
Adv Ther. 2017 May;34(5):1036-1048
pubmed: 28382557
J Clin Psychiatry. 2017 Jul;78(7):e813-e820
pubmed: 28640988
Schizophr Bull. 2018 Jun 6;44(4):778-786
pubmed: 28981851
Schizophr Res. 2018 May;195:385-390
pubmed: 29056491
Curr Opin Psychiatry. 2018 May;31(3):246-255
pubmed: 29474266
PLoS One. 2018 Feb 27;13(2):e0192929
pubmed: 29485988
Eur Psychiatry. 2018 Sep;53:58-65
pubmed: 29957369
Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:133-8
pubmed: 8866775
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
Br J Psychiatry Suppl. 1998;172(33):93-100
pubmed: 9764134